Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) FCF Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed FCF Margin for 6 consecutive years, with 7694.71% as the latest value for Q3 2023.

  • Quarterly FCF Margin fell 609289.0% to 7694.71% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 32372.53% through Jun 2024, down 3228403.0% year-over-year, with the annual reading at 112.22% for FY2023, 11475.0% up from the prior year.
  • FCF Margin for Q3 2023 was 7694.71% at Denali Therapeutics, down from 37.73% in the prior quarter.
  • The five-year high for FCF Margin was 13.29% in Q3 2020, with the low at 5024000.0% in Q1 2021.
  • Average FCF Margin over 5 years is 324664.22%, with a median of 831.62% recorded in 2019.
  • The sharpest move saw FCF Margin plummeted -502244113bps in 2021, then skyrocketed 502382862bps in 2022.
  • Over 5 years, FCF Margin stood at 780.52% in 2019, then surged by 102bps to 13.29% in 2020, then plummeted by -6744bps to 882.72% in 2021, then increased by 16bps to 738.43% in 2022, then crashed by -942bps to 7694.71% in 2023.
  • According to Business Quant data, FCF Margin over the past three periods came in at 7694.71%, 37.73%, and 175.26% for Q3 2023, Q2 2023, and Q1 2023 respectively.